{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:45Z","timestamp":1740144165969,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40273-022-01184-0","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T17:39:49Z","timestamp":1664213989000},"page":"1011-1012","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comment on \u201cCost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine\u201d"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9130-4744","authenticated-orcid":false,"given":"Nikolaos","family":"Giannelos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Lib\u00e9r\u00e9e","family":"Nishimwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Lecrenier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"issue":"4","key":"1184_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40273-021-01099-2","volume":"40","author":"Z Pieters","year":"2022","unstructured":"Pieters Z, Ogunjimi B, Beutels P, Bilcke J. Cost-effectiveness analysis of herpes zoster vaccination in 50- to 85-year-old immunocompetent Belgian cohorts: a comparison between no vaccination, the adjuvanted subunit vaccine, and live-attenuated vaccine. Pharmacoeconomics. 2022;40(4):461\u201376.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1184_CR2","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1017\/S0950268811002640","volume":"140","author":"J Bilcke","year":"2012","unstructured":"Bilcke J, Ogunjimi B, Marais C, de Smet F, Callens M, Callaert K, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012;140(11):2096\u2013109.","journal-title":"Epidemiol Infect"},{"key":"1184_CR3","unstructured":"Bilcke J, Marais C, Ogunjimi B, van Hoek AJ, Lejeune O, Callens M, Vancorenland S, Van Kerschaver E, Callaert K, Hens N, Van Damme P, Beutels P. Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium. Health Technology Assessment (HTA). KCE Reports 151; 2010. https:\/\/kce.fgov.be\/en\/publications\/all-reports\/cost-utility-of-vaccination-against-chickenpox-in-children-and-against-herpes-zoster-in-elderly-in."},{"key":"1184_CR4","unstructured":"EMA. Shingrix Summary of Product Characteristics (SmPC); 2022. https:\/\/www.ema.europa.eu\/documents\/product-information\/shingrix-epar-product-information_en.pdf"},{"key":"1184_CR5","unstructured":"EMA. Zostavax Summary of Product Characteristics (SmPC); 2022. https:\/\/www.ema.europa.eu\/documents\/product-information\/zostavax-epar-product-information_en.pdf"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01184-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01184-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01184-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T08:01:31Z","timestamp":1665475291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01184-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":5,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1184"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01184-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"assertion":[{"value":"28 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GlaxoSmithKline Biologicals SA funded all costs associated with the development and publication of this letter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NG and NL are employees of GSK and hold shares in GSK. MLN is an AIXIAL Group consultant on behalf of GSK. AIXIAL received fees from GSK for this study. The authors declare no other financial and non-financial relationships and activities and no other conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors participated in the development of this publication and gave final approval before submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}